Zealand joins next-gen club aiming to ‘accelerate’ obesity drug development

Amber Tong

As next-generation contenders in the obesity treatment space communicate plans to speed up their drug programs, Zealand Pharma appears to have gotten the memo. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Zealand joins next-gen club aiming to ‘accelerate’ obesity drug development

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development

Zealand joins next-gen club aim­ing to ‘ac­cel­er­ate’ obe­si­ty drug de­vel­op­ment

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Zealand joins next-gen club aiming to ‘accelerate’ obesity drug development